Johnson & Johnson (JNJ)
Johnson & Johnson: Remaining A Buy Despite Remaining Risks
Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit growth for the full year. The company is facing risks right now, especially from the litigations due to the talc products, and breaking the support line is also a rather bearish sign. But the stock seems slightly undervalued at this point, and Johnson & Johnson is probably a good investment for investors seeking stability and a bond-like investment.
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return
Johnson & Johnson's underlying business has a stable long-term outlook and the stock has a low volatility profile, which makes it an ideal platform for selling put options. The company is trading at a highly attractive valuation, which provides a solid margin of error. Selling put options does sacrifice capital appreciation, but with a nearly 10% annualized yield on offer, this opportunity appears to be a win-win to us.
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Dividends can boost your portfolio returns. Johnson & Johnson is a classic example of a value stock with a faithful dividend history.
Cancer victims lose bid to block proposed J&J talc bankruptcy
A federal judge on Friday rejected a bid by a group of cancer victims to block Johnson & Johnson from pursuing a proposed bankruptcy settlement of tens of thousands of lawsuits alleging the company's baby powder and other talc products contain cancer-causing asbestos.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Is Johnson & Johnson Stock a Buy?
Johnson & Johnson is trying a new approach to resolve thousands of outstanding talc lawsuits. The company's operations are growing in the mid-single digits, and investors can expect more of the same in the years ahead.
Johnson & Johnson (JNJ) Stock Declines While Market Improves: Some Information for Investors
Johnson & Johnson (JNJ) closed the most recent trading day at $147.19, moving -1.29% from the previous trading session.
Is Johnson & Johnson the Best Dividend Stock for You?
You can confidently buy and hold Johnson & Johnson indefinitely. Its steady, high-single-digit returns can stack up over time.
Two High Conviction Dividend Buys For This Upside-Down Market
FOMO is driving stock market decisions, especially with meme stocks like GameStop and high-flying AI stocks. That's why I prefer discounted dividend stocks over growth stocks, and highlight two picks that offer durable capital returns. Both names carry strong balance sheets, pay well-above market average dividend yields, and are trading at substantial discounts to their historical valuations.
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
J&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.
Johnson & Johnson (JNJ) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Johnson & Johnson (JNJ) closed at $145.65, marking a -0.21% move from the previous day.
